Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02737787
Title A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center

ovarian cancer

peritoneum cancer

fallopian tube cancer


Nivolumab + WT1 vaccine

Nivolumab + NY-ESO-1 peptide vaccine

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.